Now currently offering Covid, Flu, RSV, Shingles, and Pneumonia Vaccines.
Haworth Apothecary Logo

Get Healthy!

187 Results for search "Weight Loss".

Health News Results - 187

THURSDAY, Dec. 26, (2024 HealthDay News)  -- The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a daily injectable GLP-1 medicine for people living with Type 2 diabetes.

Liraglutide, the generic for Victoza, is similar to semaglutide, the active ingredient in the popula...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

Tirzepatide includes blockbuster injected GLP-1meds Mounjaro (for diabetes) and Zepbound (for weight loss).

The FDA first...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss meds, a new study finds.

Data on almost 17 million adults nationwide showed the obesity rate -- which has been rising for years -- fell from 46.2% of adults in 2021 to 45.6% in 2023,...

People with diabetes who are taking GLP-1 meds such as Ozempic or Mounjaro may be getting an added bonus: Reductions in their odds for a dangerous blood clot, new research finds.

The study found that folks with diab...

The advent of GLP-1 weight-loss medications such as Wegovy and Zepbound has spurred debate as to whether the drugs' cost should be covered by Medicare, Medicaid and private insurers.

Late last month, the Biden administration

  • Ernie Mundell HealthDay Reporter
  • |
  • December 5, 2024
  • |
  • Full Page
  • Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

    "Given the increased interest around obesity medications, we conducted this study to help health care providers and patients make informed decisions about treatment choice," Dr. Leonard G...

    The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found.

    Zepbound reduced the risk of diabetes in obese prediabetic patients by more than 90% during a three-year period compared to placebo, trial res...

    The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.

    However, the move would have to be approved by the new Trump administration. 

    Right now, a law passed b...

    The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm.

    In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes. 

    GLP-1s include blockbuster diabetes medicines such as Ozempic and it...

    So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where decadent food will be served in abundance.

    Luckily, one expert from Baylor College of Medicine has tips on how to enjoy holiday fare while on these medications, without overdoing it.

    GLP-1 medications, which include <...

    America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows.

    GLP-1s like Ozempic, Wegovy, Mounjaro and Zepbound

    The weight-loss drug Ozempic can help reduce stroke patients’ risk of a heart attack or death, a new study says.

    GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like

  • Dennis Thompson HealthDay Reporter
  • |
  • November 11, 2024
  • |
  • Full Page
  • It may seem counter-intuitive, but losing weight without even trying may not be a good thing.

    "It's not typical to have a noticeable drop in weight without changing how much you're eating, being more physically active or trying to lose weight," said dietitian Christine Goukasian.

    "Unexplained weight loss is a red...

    Poorer folks’ access to blockbuster weight-loss drugs through Medicaid remains limited, a new KFF analysis has found.

    Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers discovered.

    Under the Medicaid system, individual states are allowed to decide whether to cover GLP-1 drugs, which inclu...

    The GLP-1 drug semaglutide can help obese people manage debilitating knee arthritis, a new trial has found.

    People who received weekly injections of semaglutide -- the active agent in the diabetes drug Ozempic and the weight-loss medication Wegovy -- had a nearly 14% decrease in their body weight after 68 weeks, compared with 3% of people given a placebo, results showed. The trial was fun...

    The weight-loss drug Ozempic can guard against kidney disease in obese people, a new study shows.

    Patients taking semaglutide -- the active agent in Ozempic and Wegovy -- had as much as a 52% reduction in kidney damage, as measured by urine testing, researchers reported Oct. 25 in the journal ...

    As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

    Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds.

    "In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surg...

    Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says.

    People with type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer’s compared to patients taking seven other diabetes drugs, researchers reported...

    Expanding access to cutting-edge diabetes and weight-loss drugs like Ozempic and Zepbound could prevent more than 42,000 deaths a year in the United States, a new study claims.

    Obesity and all its attendant ills -- type 2 diabetes, heart disease an...

    Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a national drug shortage list.

    What prompted the FDA to reconsider its

  • Robin Foster HealthDay Reporter
  • |
  • October 15, 2024
  • |
  • Full Page
  • As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts.

    But a new study involving more than 54,000 U.S. adolescents found no such link.

    In fact, obese kids who used the drugs had a 33% decline in their risk for thoughts of suicide and suicide...

    Results from a very small study suggest that a combination of the diabetes drug Ozempic and an innovative new intestinal procedure could help erase the need for insulin in folks with type 2 diabetes.

    The new trial hasn't yet been published in a peer-reviewed journal and it included only 14 patients.

    However, Dutch researchers report that after six months of the combo therapy, 12 o...

    The key to weight loss could come down to a combination of 14 “skinny genes,” a recent study says.

    People with these genes dropped twice as much weight through regular exercise compared to those without the genes, researchers found.

    Those with the most of these genetic markers lost up to 11 pounds following eight weeks of

  • Dennis Thompson HealthDay Reporter
  • |
  • October 11, 2024
  • |
  • Full Page
  • When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows.

    In a report published Wednesday in the journal Health Affairs, researchers also found that a third of compani...

    Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy.

    Now, research finds this scenario is more likely if the patient is taking popular new weight-loss meds such as Ozempic

    In a finding that suggests Ozempic and Wegovy have powers that extend beyond weight loss, a new study finds the medications might also lower people’s risk of opioid overdose.

    People with type 2 diabetes prescribed semaglutide (Ozempic, Wegovy) had a significantly lower risk of an opioid OD t...

    During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company's high prices for its blockbuster drugs Ozempic and Wegovy.

    While testifying before the Senate Committee on Health, Education, Labor and Pens...

    Heavy-duty endurance exercise can cause body fat levels to drop without any accompanying weight loss, a new small-scale study indicates.

    A group of eleven middle-aged men who cycled 710 miles in seven days lost only about 1% of their total weight, because they ate and drank enough to offset the calorie burn.

    But they lost over 9% of their overall body fat, including a nearly 15% red...

    Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days.

    They’re in short supply, and often too expensive to afford without insurance coverage.

    Because of these barriers, many people are doing an end-run around their doctor’s office, reaching out ...

    Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that.

    In a new decades-long study, veterans with diabetes and what's known as metabolic dysfunction-associated steatotic liver disease (MASLD) were 14% less likely to progress t...

    Ozempic and its weight-loss cousin, Wegovy, outperform another longstanding weight-loss drug that targets the same hormone associated with blood sugar and appetite, a new study finds.

    Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for o...

    Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood sugar levels, a new study finds.

    Overweight or obese type 1 diabetics taking Mounjaro were able to reduce the amount of daily insul...

    Statistics from 2023 on U.S. obesity rates bring no good news: In every state in the nation, 1 in every 5 people is now obese, the new tally shows.

    In 2013, not one state had an adult obesity rate topping 35%, but 10 years later 23 states had achieved that dubious distinction, according to data ...

    The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval.

    All doses of tirzepatide consistently reduced weight in both women and men, researchers found.

    But women lost up to 25% of their initial body weight when treated with ti...

    Ozempic and Wegovy can prevent heart problems in overweight and obese people, particularly if they also suffer from kidney disease, a new clinical trial shows.

    The drugs’ active ingredient, semaglutide, reduced heart health risk by 20% in heavyset people who took it for more than three years...

    The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report.

    The findings, published Tuesday in the New England Journal of Medicine and presented simultaneously at the European Association for the Study of Diabetes annual meeting in Madrid, are the f...

    An experimental weight-loss pill appears to help people quickly shed pounds, a new study says.

    People who took the drug amycretin lost up to 13% of their body weight over three months, according to early clinical trial results presented at the European Association for the Study of Diabetes annual meeting in Madrid.

    Amycretin mimics the action of two different hunger-related hormones...

    Losing weight can help a person with obesity -- especially those with diabetes -- fend off serious infections, new data shows.

    It's an important finding, since "up to one in three hospitalizations in people with diabetes are for infections and people with diabetes are twice as likely to be hospitalized with infections than the general population. They are also at high risk of readmission,...

    A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the weekly injections they now take, a new study demonstrates.

    The new formulation encases semaglutide in a hydrogel that slowly releases the drug as the gel dissolves, researchers...

    The booming popularity of the weight-loss drug semaglutide has prompted increasing concerns about potential side effects from taking Ozempic or Wegovy.

    But a new study rules out one possible problem -- using semaglutide does not increase a person&rsq...

    Folks taking weight-loss drugs like Wegovy or Zepbound might think they’ve found a shortcut to better health.

    But they still need to eat a high-quality diet if they want to maintain their well-being while they shed pounds, says a doctor with ...

    New trials are showing how the blockbuster diabetes and weight-loss meds Ozempic and Wegovy can boost health in even more ways.

    These two injected drugs are versions of semaglutide. In multiple new data analyses, the drugs appeared to cut people's odds for heart failure and its complications, reduce deaths from COVID-19 and lower deaths...

    Breastfeeding helps women shed those extra pounds of "pregnancy weight," a new study finds, and the effect is even more pronounced for moms who were overweight before their pregnancy.

    Among women who exclusively breastfed their baby during its first year, women who were normal weight prior to pregnancy lost weight, but still retained about three extra pounds of their pregnancy weight, re...

    New Medicare rules could make 3.6 million Americans -- or even more -- eligible for treatment with the pricey weight-loss drug Wegovy, a new study finds.

    Under the new rules, the government will pay for Wegovy treatment if a person with high BMI also has heart disease.

    Until now, federal reg...

    A study of more than 400,000 people tracked for up to 24 years finds that those who got their dietary fat from plants versus animals had significantly lower odds of dying during the study period.

    Plant-based fats' benefit included a reduced odds for deaths due to heart disease, the research showed.

    Conversely, the study "provides evidence that diets high in animal-based fats, includ...

    WEDNESDAY, Aug. 7, 2024 (HealthDay news) -- Medicare and Medicaid patients are less likely to get cutting-edge weight-loss drugs than people with private insurance are, a new study finds.

    Medicaid accounted for less than 10% of semaglutide (Ozempic, Wegovy) prescription fills in 2023, researchers ...

    Two new studies show how eager Americans are to obtain either safe, legitimate versions of Ozempic or counterfeit and potentially dangerous forms of the diabetes/weight-loss drug.

    One study found U.S. prescriptions and refills of Ozempic (semaglutide) soari...

    The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 diabetes, a new study finds. 

    New prescriptions for these drugs have doubled among people who have obesity but not diabetes, investigators...

    Nearly half of cancer deaths and 4 of 10 cases of cancer are linked to a person's lifestyle, a new study says.

    Cigarette smoking remains the biggest cancer risk, contributing to 30% of cancer deaths and 20% of cancer cases, results show.

    But excess body weight, drinking, lack of exercise, diet and skipping cancer-preventing vaccinations also increase a person's risk of developing or...

    Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new analysis shows.

    Conducted by Prime Therapeutics and Magellan Rx Management (MRx), the review sifted through pharmacy and medical c...